Global Regulatory Agencies Update Real-World Evidence Guidance for Decision-Making
Decision brief
Answer first · skim in under a minute
Regulatory bodies worldwide are refining their guidance on the use of real-world evidence (RWE) to inform drug approval and post-market surveillance. This evolution presents new opportunities and challenges for pharmaceutical companies seeking to leverage RWE in their regulatory strategies.
Global regulatory agencies update real-world evidence guidance expectations into 2026: FDA finalised an updated device RWE guidance in December 2025, while EMA advanced its RWE roadmap, non-interventional reflection paper and annual regulator-led study reports—raising the bar for data quality before RWE can support decisions.
Contents9 sections
Key Takeaways
- FDA device RWE final guidance (18 Dec 2025) supersedes 2017 text; eSTAR updated for 2026 submissions.
- EMA reflection paper on RWD in non-interventional studies: published 3 April 2025 (EMA/99865/2025).
- EMA fourth RWE experience report covers regulator-led studies Feb 2025–Feb 2026.
- ICH E23 work continues—global RWE rules are not yet fully aligned.
What did FDA update for real-world evidence?
FDA’s page on Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices states the document supersedes the 31 August 2017 final guidance and clarifies how FDA evaluates whether real-world data are sufficient to generate RWE for device decisions.
Agency webinar materials timed to February 2026 emphasise relevance and reliability assessments, FDORA Section 3629 drivers, MDUFA V commitments, and revised eSTAR fields sponsors should be ready to populate.
How is EMA structuring RWE guidance?
EMA’s real-world evidence hub hosts the roadmap for RWE guidance, Q&As on real-world data use, and successive reports on regulator-led studies, including the fourth report spanning February 2025 to February 2026.
The reflection paper on RWD in non-interventional studies (EMA/99865/2025) sets methodological expectations for generating RWE for regulatory purposes and distinguishes non-interventional studies from clinical trials under Regulation (EU) No 536/2014.
What should global pharma teams change in 2026?
- Map which claims are device versus medicinal-product RWE pathways—FDA’s December 2025 final is device-focused.
- Budget for data provenance, fitness-for-purpose and protocol transparency before pitching RWE to regulators.
- Track ICH E23 drafts for future effectiveness-decision convergence.
Related reading: EMA new EU pharma rules, China oncology trial share, and ASCO 2026 cancer care barriers.
How should APAC sponsors operationalise RWE in 2026?
For Asia-Pacific filings that later bridge to FDA or EMA, start with a written fitness-for-purpose memo that names the decision the RWE is meant to support—label expansion, safety signal, or external control—and the estimand that matches that decision.
Build source-system documentation early: coding dictionaries, missingness patterns, linkage methods and governance of updates. FDA’s device guidance and EMA’s reflection paper both treat provenance and reliability as gatekeepers, not afterthoughts for the discussion section.
Where sponsors plan multi-region packages, maintain a delta table that lists which RWE claims are US-device pathway, which are EU medicinal-product pathway, and which remain exploratory. That table becomes the briefing spine for agency meetings and reduces copy-paste errors across dossiers.
What remains unharmonised?
Submission formats, acceptable external-control designs and post-marketing RWE expectations still differ by agency. Sponsors that copy-paste one region’s RWE package into another will face questions on relevance, reliability and estimands.
Related NovaPharma coverage
Frequently Asked Questions
What did FDA change in its device RWE guidance?
FDA’s final guidance Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices (published 18 December 2025; operationalised into 2026) supersedes the 2017 version, expands recommendations on relevance and reliability of real-world data, and aligns eSTAR content with FDORA and MDUFA V commitments.
What is EMA doing on RWE guidance?
EMA maintains an RWE framework page with a roadmap for regulatory guidance, a reflection paper on using real-world data in non-interventional studies (first published 3 April 2025), and a fourth report on regulator-led RWD studies covering February 2025–February 2026.
Are FDA and EMA RWE rules fully harmonised?
No. EMA notes ongoing ICH E23 work on RWE for effectiveness decision-making precisely because global convergence is incomplete. Sponsors still need jurisdiction-specific protocols for data quality, study design and submission format.
Primary Sources
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
